Lunai Bioworks (LNAI) Income towards Parent Company (2011 - 2026)
Lunai Bioworks (LNAI) recorded quarterly Income towards Parent Company of -$1.6 million in Q1 2026, up 18.49% quarter-over-quarter from -$1.9 million in Q4 2025, and up 63.57% on a YoY basis from -$969219.1 in Q1 2025.
Lunai Bioworks (LNAI) Income towards Parent Company (2011 - 2026) Analysis & Trends
Lunai Bioworks' Income towards Parent Company history runs 16 years deep, the most recent figure standing at -$1.6 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 63.57% year-over-year to -$1.6 million; the TTM figure through Mar 2026 stood at -$134.1 million (down 67.97% YoY), while the FY2025 annual figure was -$189.7 million, down 129.51% from the prior year.
- Income towards Parent Company was -$1.6 million for Q1 2026 at Lunai Bioworks, up from -$1.9 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$1.6 million in Q1 2026 to a low of -$127.1 million in Q2 2025.
- Historically, Income towards Parent Company has averaged -$24.4 million across 5 years, with a median of -$6.2 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company slumped 1094.49% in 2024, then soared 93.58% in 2025.
- A 5-year view of Income towards Parent Company shows it stood at -$4.5 million in 2022, then declined by 1.96% to -$4.5 million in 2023, then decreased by 2.2% to -$4.6 million in 2024, then jumped by 58.13% to -$1.9 million in 2025, then advanced by 18.49% to -$1.6 million in 2026.
- The last three Income towards Parent Company figures came in at -$1.6 million (Q1 2026), -$1.9 million (Q4 2025), and -$3.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Lunai Bioworks | 95.85 Mn | 92.70 Mn | 20,942.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.59 Mn |
| Dec 31, 2025 | -1.94 Mn |
| Sep 30, 2025 | -3.43 Mn |
| Jun 30, 2025 | -127.11 Mn |
| Mar 31, 2025 | -4.35 Mn |
| Dec 31, 2024 | -4.65 Mn |
| Sep 30, 2024 | -53.46 Mn |
| Jun 30, 2024 | -17.36 Mn |
| Mar 31, 2024 | -51.70 Mn |
| Dec 31, 2023 | -4.55 Mn |
| Sep 30, 2023 | -9.18 Mn |
| Jun 30, 2023 | -23.20 Mn |
| Mar 31, 2023 | -4.33 Mn |
| Dec 31, 2022 | -4.46 Mn |
| Sep 30, 2022 | -7.70 Mn |
| Jun 30, 2022 | -90.24 Mn |
| Mar 31, 2022 | -6.20 Mn |
| Dec 31, 2021 | -6.58 Mn |
| Sep 30, 2021 | -10.41 Mn |
| Jun 30, 2021 | -17.36 Mn |